Last updated: April 28, 2026
Omnipaque 350 (iohexol) Clinical Trials Update, Market Analysis, and Projection
What is Omnipaque 350 and what is its current clinical footprint?
Omnipaque 350 is a branded, iodine-based radiographic contrast product containing iohexol 350 mg I/mL for intravascular and intrathecal use in diagnostic imaging. It is a long-established, off-patent small-molecule contrast agent. Competitive positioning is driven by supply reliability, perceived tolerability, formulary access, and contracting, not by new primary clinical efficacy claims.
Evidence base structure for current market relevance
- No late-stage “program” refresh cadence: Omnipaque is not a development-stage pipeline product; market movement is governed by guideline-based utilization of iodinated contrast, channel mix (hospital vs. office-based imaging), and payer/formulary decisions.
- Clinical use remains protocol-driven: Utilization patterns depend on imaging modality (CT angiography, CT abdomen/pelvis, CT trauma), patient risk management (renal impairment protocols), and institutional contrast stewardship (rate of injection, hydration pathways).
Trial activity reality check (what matters for decisions)
- For Omnipaque 350 specifically, the practical clinical landscape is dominated by:
- Comparative equivalence or switching studies among iodinated contrast products (brand-to-generic, or brand-to-brand switching) used to support contracting and substitution.
- Safety monitoring studies focused on real-world adverse event rates and renal outcomes.
- The product’s market value is therefore linked to ongoing post-marketing and comparative evidence rather than to incremental phase 2/3 endpoints.
What clinical trials are most likely to influence Omnipaque 350 demand now?
Without new, brand-defining phase 3 readouts, demand is influenced by trials and real-world evidence that change local protocols. The trials that typically drive formulary or pathway adoption for iodinated contrasts include:
- Renal risk mitigation pathways
- Trials and registries that support hydration strategies, hemodialysis timing approaches (when relevant), and contrast dose minimization.
- Adverse event characterization
- Work that improves stratification of hypersensitivity risk and standardizes premedication pathways.
- Injection regimen and workflow efficiency
- Studies on injection rate, viscosity handling, and workflow integration for CT protocols.
For Omnipaque 350, these elements influence:
- use of higher iodine concentration regimens for angiography and contrast timing,
- adherence to protocols that reduce renal adverse events,
- preference for brands with strong supply continuity for large-batch imaging schedules.
How big is the iodinated contrast market and where does Omnipaque 350 sit?
Omnipaque 350 competes in the broader iodinated contrast media segment used primarily for CT and angiography.
Market demand drivers
- CT utilization growth in oncology, trauma, stroke pathways, and cardiology imaging.
- Expansion of emergency imaging volume.
- Aging demographics and higher comorbidity prevalence, which increases the need for robust renal risk protocols.
- Substitution pressure from generics and authorized distributors, which keeps pricing mostly contracting in mature geographies.
Competitive structure
- Brand-to-generic competition for formulation- and concentration-specific SKUs (e.g., 300 vs. 320 vs. 350 mg I/mL).
- Tender-driven procurement in hospital systems.
- Pre-authorization dynamics in some payer contexts are less important than supply and protocol fit.
What is the pricing and substitution outlook for Omnipaque 350?
Omnipaque is mature; substitution risk is structural. The key pricing variables are:
- Contracting volume and distributor terms.
- Switching flexibility among equivalent concentrations and osmolality profiles (where the clinical protocol allows).
- Tender outcomes that prioritize unit cost and supply reliability.
Because Omnipaque 350 is widely available as an established SKU, procurement often results in:
- periodic tender-driven price compression,
- channel consolidation toward a small set of contracted suppliers,
- increased use of multi-source panels rather than single-brand exclusivity.
What is the competitive map for 350 mg I/mL iodinated contrasts?
Omnipaque 350 competes with other iodinated contrast agents formulated for CT and angiography. Key competitive dimensions:
- iodine concentration (350 mg I/mL),
- osmolality class and physicochemical handling,
- viscosity at use temperature,
- packaging formats and injection compatibility (including power injection compatibility),
- documented safety and tolerability in real-world settings.
What does the pipeline look like: is there an Omnipaque 350 “trial program” to underwrite growth?
Growth from R&D is not the dominant mechanism for Omnipaque 350. Demand growth is more closely tied to:
- imaging volume growth,
- substitution economics,
- hospital contracting cycles,
- guideline adherence and protocol standardization.
Market projection: what happens to Omnipaque 350 volumes and pricing through 2030?
A practical projection for Omnipaque 350 needs to separate:
- volume (imaging utilization and concentration preference),
- price (tender cycles, generic pressure, and contracting discipline).
Volume projection logic (high level)
- CT volumes rise with oncology surveillance, cardiovascular imaging, and emergency department throughput.
- 350 mg I/mL concentrates are retained in angiography and fast-timing CT protocols where iodine delivery rate matters.
- Peak growth comes from procedure volume expansion rather than new clinical indications.
Price projection logic (high level)
- Pricing trends typically show:
- downward or flat pricing in mature markets,
- temporary stabilization in markets where contracting uses a limited supplier panel,
- continued erosion where generics and authorized alternatives maintain competitive unit costs.
Scenario projection (directional)
Base case (most likely for mature, off-patent brands)
- Volume: grows roughly in line with CT procedure growth.
- Price: declines slowly via tender pressure, offset partially by concentration preference in protocolized workflows.
Downside (tender and substitution headwinds)
- Volume: slower growth due to aggressive multi-source switching and procurement consolidation to lowest-cost suppliers.
- Price: faster decline in unit pricing during procurement cycles.
Upside (channel and supply stability)
- Volume: faster penetration where systems enforce tighter contrast handling protocols and where supply reliability prevents outages.
- Price: flatter than expected due to inclusion in contracted panels.
Where are the commercial “hinge points” for Omnipaque 350?
- Hospital formularies and contrast panels
- Once a system standardizes a contrast panel for CT protocols, substitution risk declines until the next tender cycle.
- CT angiography adoption and protocol timing
- High iodine concentration selection supports consistent CTA performance, sustaining demand for 350 mg I/mL SKUs.
- Renal risk pathways
- Brands that align with local renal safety pathways and are consistently available maintain utilization.
- Tender frequency and procurement leverage
- Multi-year contracts with index-based adjustments can dampen near-term pricing erosion, but not long-term compression.
Regulatory and label considerations affecting adoption
Omnipaque’s commercial usage is influenced by:
- compatibility with institutional protocols for intravascular and intrathecal imaging,
- safety warnings and risk management practices aligned with iodinated contrast labeling,
- administration requirements, including patient hydration and hypersensitivity preparedness.
Key Takeaways
- Omnipaque 350 is a mature iohexol brand where growth and competitiveness depend on imaging utilization, protocol standardization, and contracting economics, not on new late-stage clinical development.
- Clinical influence comes from renal risk mitigation, adverse event characterization, and workflow/injection regimen studies that shape how hospitals select and standardize iodinated contrast media.
- The market outlook through 2030 is primarily a volume-growth, price-compression profile typical for off-patent contrast products.
- The commercial hinge points for Omnipaque 350 are formulary inclusion, tender cycle outcomes, and concentration-specific protocol use, especially for CT angiography and time-critical imaging.
FAQs
1) Is Omnipaque 350 still a development-stage product with new phase 3 trials?
No. Omnipaque 350 is a mature, off-patent iodinated contrast agent. Market relevance is driven by protocol uptake and procurement rather than new phase 3 pivotal trials.
2) What most influences hospital switching between iodinated contrast brands?
Tender pricing, supply continuity, compatibility with established injection protocols, and how closely the brand’s real-world safety profile aligns with the hospital’s renal risk and hypersensitivity pathways.
3) Why do 350 mg I/mL iodinated contrasts remain important?
Higher iodine concentration supports iodine delivery rates used in contrast-timed CT workflows, especially angiography and time-critical imaging where protocol performance depends on consistent contrast kinetics.
4) Does renal risk management drive demand for Omnipaque 350?
Yes. Institutions that standardize hydration and monitoring pathways influence which contrast agents are consistently used and retained on contrast panels.
5) What is the main risk to Omnipaque 350 unit pricing?
Generic and authorized alternative substitution combined with tender-driven procurement that pushes unit costs down in mature markets.
References (APA)
[1] FDA. (n.d.). Drug label and approvals for iohexol-containing radiographic contrast products (Omnipaque/related entries). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
